Physician profile
Laura Sices
NPI 1417974320
$452.72
in general payments reported to CMS, 2019-2025
12 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Developmental - Behavioral Pediatrics provider received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.05 · 2024: $275 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $60.21 | 2024 | Daybue |
| Ascendis Pharma Endocrinology INC | $59.77 | 2024-2025 | Skytrofa |
| Ucb, INC. | $48.15 | 2024-2025 | Nayzilam |
| Neurelis, INC. | $47.30 | 2024 | Valtoco |
| Sanofi-Aventis U.S. LLC | $37.89 | 2025 | |
| Soleno Therapeutics, INC. | $37.26 | 2025 | Vykat Xr |
| Sk Life Science, INC. | $35.67 | 2024 | |
| Tandem Diabetes Care, INC. | $31.71 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Genentech USA, INC. | $30.80 | 2024 | Hemlibra |
| Qol Medical, LLC | $27.25 | 2024 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $21.66 | 2025 | Dupixent |
| Abbott Laboratories | $15.05 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Sices listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.